Silva Zupančić‐Šalek

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark et al. · Blood · 2019 · 145 citations · Full text

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Johnny Mahlangu, Karin Weldingh, Steven R. Lentz et al. · Journal of Thrombosis and Haemostasis · 2015 · 59 citations · Full text

Clinical Immunology, Molecular Immunology, Immunogenetics +9

Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B

Lynne M. Smith, Kazimierz Kuliczkowski, Joan Korth‐Bradley et al. · Haemophilia · 2016 · 52 citations · Full text

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark et al. · Blood Advances · 2022 · 42 citations · Full text

Immunohematology, Thrombosis, Long-term Efficacy +13

Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms

Ivana Horvat, Ana Boban, Renata Zadro et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 40 citations

Hematological Malignancy, Thrombosis, Blood Count +10